T cell acute lymphoblastic leukemia (T-ALL) is a highly aggressive blood cancer with high unmet needs. The focus of our laboratory is to identify areas of unmet need and mechanisms of resistance potentially addressable via targeted therapies in high-risk ALL. We have identified that splicing factors are aberrantly regulated via deubiquitination from a protein called USP7 that is enriched in high-risk leukemia. We show this might be a key event in T-ALL initiation and progression. In this proposal, we aim to understand the mechanisms of this regulation, and therapeutically target aberrant deubiquitination and splicing using small molecule inhibitors in highly relevant xenograft models of disease.
|Effective start/end date||1/1/18 → 3/31/21|
- Gabrielle's Angel Foundation For Cancer Research (Agreement 3/29/18)